Oncogenic potential of yin yang 1 mediated through control of imprinted genes

Critical Reviews in Oncogenesis

Volumn 16, Issue 3-4, 2011, Pages 199-209

  Thiaville, Michelle M ^a   Kim, Joomyeong ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Alpha stimulating; Cancer; Guanine nucleotide binding protein; Imprinting; Imprinting control region; Paternally expressed gene three; YY1

Indexed keywords

DNA BINDING PROTEIN; TRANSCRIPTION FACTOR YY1;

BINDING SITE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; EDITORIAL; GENE CONTROL; GENETIC CONSERVATION; GENOME IMPRINTING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

EID: 84862913180     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v16.i3-4.40     Document Type: Editorial

References (64)

1. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 1991;67:377-388.
2. Park K, Atchison ML. Isolation of a candidate repressor/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin kappa 3' enhancer and the immunoglobulin heavy-chain mu E1 site. Proc Natl Acad Sci USA. 1991;88:9804-9808.
3. Hariharan N, Kelley DE, Perry RP. Delta, a transcription factor that binds to downstream elements in several polymerase II promoters, is a functionally versatile zinc fnger protein. Proc Natl Acad Sci USA. 1991;88:9799-9803.
4. Shi Y, Lee JS, Galvin KM. Everything you ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1997;1334:F49-F66.
5. Tomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene. 1999;236:197-208.
6. Liu H, Shi Y. Yin Yang 1. In: Iuchi S, Kuldell N (eds). Zinc Finger Proteins: From Atomic Contact to Cellular Function. New York: Springer; 2005.
7. Gordon S, Akoryan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Onco-gene. 2006;25:1125-1142.
8. Calame K, Atchison M. YY1 helps to bring loose ends together. Genes Dev. 2007;21:1145-1152.
9. Schug J, Schuller WP, Kappen C, Salbaum JM, Bucan M, Stoeckert CJ Jr. Promoter features related to tissue specifcity as measured by Shannon entropy. Genome Biol. 2005;6:R33.
10. Afarel B, Gay F, Shi Y, Liu H, Huarte M, Wu S, et al. Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol. 2006;26:3565-3581.
11. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, et al. Te involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle. 2009;8:1367-1372.
12. Kim J. Multiple YY1 and CTCF binding sites in imprinting control regions. Epigenetics. 2008;3:115-118.
13. Kim JD, Hinz AK, Bergmann A, Huang JM, Ovcharenko I, Stubbs L, et al. Identifcation of clustered YY1 binding sites in imprinting control regions. Genome Res. 2006;16:901-911.
14. Hirasawa R, Feil R. Genomic imprinting and human disease. Essays Biochem. 2010;48:187-200.
15. Lim DH, Maher ER. Genomic imprinting syndromes and cancer. Adv Genet. 2010;70:145-175.
16. Kim JD, Faulk C, Kim J. Retroposition and DNA-binding motifs of YY1, YY2 and REX1. Nucleic Acids Res. 2007;35:3442-3452.
17. Wilkinson FH, Park K, Atchison ML. Poly-comb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci USA. 2006;103:19296-192301.
18. Wilkinson F, Pratt H, Atchison ML. PcG recruitment by the YY1 REPO domain can be mediated by Yaf2. J Cell Biochem. 2010;109:478-486.
19. Hyde-DeRuyscher RP, Jennings E, Shenk T. DNA binding sites for the transcriptional activator/repres-sor YY1. Nucleic Acids Res. 1995;23:4457-4465.
20. Yant SR, Zhu W, Millinof D, Slightom JL, Goodman M, Gumucio DL. High afnity YY1 binding motifs: identifcation of two core types (ACAT and CCAT) and distribution of potential binding sites within the human beta globin cluster. Nucleic Acids Res. 1995; 23:4353-4362.
21. Kim J, Kim J. YY1's longer DNA-binding motifs. Genomics. 2009;93:152-158.
22. Kwon S-H, Kim SH, Chung H-M, Girton JR, Jeon S-H. Te Drosophila pleiohomeotic mutation enhances the Polycomblike and Polycomb mutant phenotypes during embryogenesis and in the adult. Int J Dev Biol. 2003;47:389-395.
23. Luo C, Lu X, Stubbs L, Kim J. Rapid evolution of a recently retroposed transcription factor YY2 in mammalian genomes. Genomics. 2006;87:348-355.
24. Oei SL, Babich VS, Kazakov VI, Usmanova NM, Kropotov AV, Tomilin NV. Clusters of regulatory signals for RNA polymerase II transcription associated with Alu family repeats and CpG islands in human promoters. Genomics. 2004;83:873-882.
25. Khan H, Smit A, Boissinot S. Molecular evolution and temporal amplifcation of human LINE-1 ret-rotransposons since the origin of primates. Genome Res. 2006;16:78-87.
26. Carroll SB, Grenier JK, Weatherbee SD. From DNA to Diversity: Molecular Genetics and the Evolution of Animal Design. Malden, MA: Blackwell Science; 2001:97-121.
27. Davidson EH. Genomic Regulatory Systems: Development and Evolution. San Diego, CA: Academic Press; 2001:1-23.
28. Kim JD, Yu S, Kim J. YY1 is autoregulated through its own DNA-binding sites. BMC Mol Biol. 2009;10:85.
29. Bartolomei MS. Genomic imprinting: employing and avoiding epigenetic processes. Genes Dev. 2009;23:2124-2133.
30. Kim JD, Hinz AK, Choo JH, Stubbs L, Kim J. YY1 as a controlling factor for the Peg3 and Gnas imprinted domains. Genomics. 2007;89:262-269.
31. Kim J, Kim JD. In vivo YY1-knockdown efects on genomic imprinting. Hum Mol Genet. 2008;17:391-401.
32. Kim JD, Kang K, Kim J. YY1's role in DNA methylation of Peg3 and Xist. Nucleic Acids Res. 2009;37:5656-5664.
33. Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle. 2010;9:512-522.
34. Liu Q, Merkler KA, Zhang X, McLean MP. Pros-taglandin F2 Suppresses Rat Steroidogenic Acute Regulatory Protein Expression via Induction of Yin Yang 1 protein and recruitment of histone deacety-lase 1 protein. Endocrinology. 2007;148:5209-5219.
35. Han S, Lu J, Zhang Y, Cheng C, Li L, Han L, et al. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. Immunol Lett. 2007;108:143-150.
36. Coull JJ, Romerio F, Sun J, Volker JL, Galvin KM, Davie JR, et al. Te human factors YY1 and LSF repress the human immunodefciency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol. 2000;74:6790-6799.
37. Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of a3b1-integrin in tumour cells. Oncogene. 2007;26:382-394.
38. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/enhancer-binding protein activity by YY1/Polycomb group/ DNA methyltransferase complex. J Biol Chem. 2008;283(45):30919-30932.
39. Iacobuzio-Donahue C. Epigenetic changes in cancer. Annu Rev Pathol Mech Dis. 2009;4:229-249.
40. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA. 1989;86:7480-7484.
41. Mannens M, Hoovers JM, Redeker E, Verjaal M, Feinberg AP. Parental imprinting of human chromosome region 11p15.3-pter involved in the Beckwith-Wiedemann syndrome and various human neoplasia. Eur J Hum Genet. 1994;2:3-23.
42. Dowdy SC, Gostout BS, Shridhar V, Wu X, Smith DI, Podratz KC, et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol. 2005;99:126-134.
43. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa J P, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008;112:1489-1502.
44. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117:4424-4438.
45. Kohda T, Asai A, Kuroiwa Y, Kobayashi S, Aisaka K, Nagashima G, et al. Tumour suppressor activity of human imprinted gene PEG3 in a glioma cell line. Genes Cells. 2001;6:237-247.
46. Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishi-hara S, Shirayoshi Y, et al. Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog. 2001;31:1-9.
47. Otsuka S, Maegawa S, Takamura A, Kamitani H, Watanabe T, Oshimura M, et al. Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85:157-165.
48. Shibui T, Higo Y, Tsutsui TW, Uchida M, Oshimura M, Barrett JC, et al. Changes in expression of imprinted genes following treatment of human cancer cell lines with non-mutagenic or mutagenic carcinogens. Int J Oncol. 2008;33:351-360.
49. Hashimoto K, Azuma C, Tokugawa Y, Nobunaga T, Aki TA, Matsui Y, et al. Loss of H19 imprinting and up-regulation of H19 and SNRPN in a case with malignant mixed Müllerian tumor of the uterus. Hum Pathol. 1997;28:862-865.
50. Bussey KJ, Lawce HJ, Himoe E, Shu XO, Heerema NA, Perlman EJ, et al. SNRPN methylation patterns in germ cell tumors as a refection of primordial germ cell development. Genes Chromosomes Cancer. 2001;32:342-352.
51. Lee SH, Appleby V, Jeyapalan JN, Palmer RD, Nicholson JC, Sottile V, et al. Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells. J Neurooncol. 2011;101:419-428.
52. Korshunov A, Sycheva R, Golanov A. Genetically distinct and clinically relevant subtypes of glioblas-toma defned by array-based comparative genomic hybridization (array-CGH). Acta Neuropathol. 2006;111:465-474.
53. Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2010;34:148-153.
54. Davies HD, Leusink GL, McConnell A, Deyell M, Cassidy SB, Fick GH, et al. Myeloid leukemia in Prader-Willi syndrome. J Pediatr. 2003;142:174-178.
55. Rodriguez-Jato S, Nicholls RD, Driscoll DJ, Yang T P. Characterization of cis- and trans-acting elements in the imprinted human SNURF-SNRPN locus. Nucleic Acids Res. 2005;33:4740-4753.
56. Tominaga E, Tsuda H, Arao T, Nishimura S, Takano M, Kataoka F, et al. Amplifcation of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2010;118:160-166.
57. Mantovani G, Lania AG, Spada A. GNAS imprinting and pituitary tumors. Mol Cell Endocrinol. 2010;326:15-18.
58. Frey UH, Fritz A, Rotterdam S, Schmid KW, Potthof A, Altmeyer P, et al. GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma. Eur J Med Res. 2010;15:422-427.
59. Wu J, Matthaei H, Maitra A, Dal-Molin M, Wood LD, Eshleman JR, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92-166.
60. Sirchia SM, Tabano S, Monti L, Recalcati MP, Gariboldi M, Grati FR, et al. Misbehaviour of XIST RNA in breast cancer cells. PLoS One. 2009;4:e5559.
61. Weakley SM, Wang H, Yao Q, Chen C. Expression and function of a large non-coding RNA gene XIST in human cancer. World J Surg. 2011;35:1751-1756
62. Gibb EA, Brown CJ, Lam WL. Te functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.
63. Agrelo R, Wutz A. ConteXt of change--X inactiva-tion and disease. EMBO Mol Med. 2010;2:6-15.
64. Jeon Y, Lee J T. YY1 tethers Xist RNA to the inactive X nucleation center. Cell. 2011;146:119-133.